脂肪酸合成酶基因的N6‐甲基腺苷异常 修饰与2型糖尿病的关联性研究.

A total of 40 T2DM patients and 50 healthy controls who underwent carotid endarterectomy in the Department of Neurointerventional Intervention, Xuanwu Hospital, Capital Medical University from December 2021 to December 2022 were selected for this study. Real‑time fluorescence quantitative polymerase chain reaction (RT‑qPCR) and RNA methylation immunoprecipitation quantitative polymerase chain reaction (MeRIP‑qPCR) techniques were applied to determine the level of FASN mRNA expression and m6 A modification of FASN mRNA in their adipose tissues. Subsequently, a nested case‑control study design was used in “Functional Community Cohort” from 2018 to 2023 at the Health Management Center of Xuanwu Hospital of Capital Medical University. With 2018 as the baseline, new‑onset T2DM patients after 5 years were used as the new‑onset T2DM group (87 cases), and healthy controls were used as the control group according to the 1∶ 1 individual matching method, and the results were validated in peripheral blood. The t‑test was used to compare the differences in the expression levels of FASN mRNA and the m6 A modification levels of FASN mRNA between different groups, and Spearman correlation was used to analyze the correlation between them. Multifactorial binary logistic regression models were used to assess the strength of the association between the m6 A modification level of FASN mRNA and T2DM. Receiver operating characteristic (ROC) curves were constructed to evaluate the ability of m6 A modification levels of FASN mRNA to predict T2DM. Results FASN mRNA was highly expressed in T2DM patients (1.30±0.38 vs. 0.70±0.30 for adipose tissue, P<0.001; 1.25±0.76 vs. 1.02±0.45 for peripheral blood, P<0.01), and the m6 A modification level of FASN mRNA was low in T2DM patients (0.53±0.24 vs. 0.84±0.53 for adipose tissue, P<0.001; 0.67±0.55 vs. 1.54±0.87 for peripheral blood, P<0.001) both in adipose tissue and peripheral blood. FASN mRNA and m6 A modification level of FASN mRNA were negatively correlated (adipose tissue r=-0.360, P<0.001; peripheral blood r=-0.192, P<0.05). Baseline low m6 A modification level of FASN mRNA was a risk factor of T2DM in peripheral blood (OR=5.71, 95%CI 1.73-18.85). The ROC curve for the T2DM prediction model showed that the m6 A modification level of FASN mRNA was a good predictor of T2DM (area under the ROC curve was 0.817, 95%CI 0.753-0.888). Conclusion Abnormal m6 A modification of FASN mRNA was linked to T2DM, and the m6 A modification level of FASN mRNA can predict the risk of developing T2DM. [ABSTRACT FROM AUTHOR]